Chiasma Responds To FDA Complete Response With 33% Staff Cut
This article was originally published in The Pink Sheet Daily
Executive Summary
With a near-term launch of Mycapssa unlikely, Chiasma cuts its commercial staff while it evaluates how to respond to an April complete response letter.